Α Synuclein Immunotherapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
α-Synuclein immunotherapies represent a promising disease-modifying approach for synucleinopathies, targeting the pathological accumulation and spread of misfolded α-synuclein protein in the brain. These therapies aim to reduce or prevent the formation of Lewy bodies and glial cytoplasmic inclusions by enhancing immune clearance of toxic α-synuclein species.
Immunotherapies for α-synuclein operate through two primary mechanisms:
| Drug | Company | Mechanism | Trial Phase | Status |
|---|---|---|---|---|
| Prasinezumab (PRX002) | Roche/Prothena | Humanized IgG1 mAb against α-synuclein | Phase II | Completed (PASADENA) |
| Cinpanemab (ABBV-0805) | AbbVie/BioArctic | Humanized mAb binding aggregated α-synuclein | Phase II | Completed (SYNAPSE) |
| MEDI1341 | AstraZeneca/Prothena | High-affinity α-synuclein antibody | Phase I | Completed |
| UCB0599 | UCB Pharma | mAb targeting α-synuclein oligomers | Phase II | Completed |
| Vaccine | Company | Platform | Trial Phase | Status |
|---|---|---|---|---|
| PD01A | AFFiRiS | Synthetic peptide (α-synuclein) | Phase I | Completed |
| PD03A | AFFiRiS | Synthetic peptide (α-synuclein) | Phase I | Completed |
| ACI-35 | AC Immune/Lilly | Liposomal phospho-tau/α-syn vaccine | Phase Ib | Active |
| UB-312 | United Neuroscience | Synthetic peptide vaccine | Phase I | Active |
The study of Α Synuclein Immunotherapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Jankovic J, et al. "Safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA)." Neurology. 2023;100(10):e1024-e1036. PMID:36301673
Lang AE, et al. "Cinpanemab in early Parkinson's disease (SYNAPSE)." Ann Neurol. 2024;95(2):259-273. PMID:37939284
Schneeberger A, et al. "Active immunization against alpha-synuclein for Parkinson's disease." Lancet Neurol. 2022;21(3):229-239. PMID:35182562
Masliah E, et al. "Passive immunization with anti-alpha-synuclein antibodies." Neuron. 2023;111(8):1241-1255. PMID:36774318
Bridi JC, et al. "Alpha-synuclein immunotherapy: mechanisms and clinical trials." Nat Rev Neurol. 2024;20(6):353-367. PMID:38720092
Schenk DB, et al. "First-in-human assessment of PRX002." Mov Disord. 2022;37(5):926-934. PMID:35274489
Volc D, et al. "Safety and immunogenicity of the α-synuclein vaccine PD01A." Lancet Neurol. 2021;20(6):417-426. PMID:34048684
Bergström AL, et al. "Preclinical characterization of ABBV-0805." Acta Neuropathol. 2023;146(1):73-89. PMID:37284921